The importance of antimicrobial resistance in medical mycology.
Neil A R GowCarolyn JohnsonJudith BermanAlix T CosteChristina A CuomoDavid S PerlinTihana BicanicThomas S HarrisonNathan P WiederholdMichael J BromleyTom ChillerKeegan EdgarPublished in: Nature communications (2022)
Prior to the SARS-CoV-2 pandemic, antibiotic resistance was listed as the major global health care priority. Some analyses, including the O'Neill report, have predicted that deaths due to drug-resistant bacterial infections may eclipse the total number of cancer deaths by 2050. Although fungal infections remain in the shadow of public awareness, total attributable annual deaths are similar to, or exceeds, global mortalities due to malaria, tuberculosis or HIV. The impact of fungal infections has been exacerbated by the steady rise of antifungal drug resistant strains and species which reflects the widespread use of antifungals for prophylaxis and therapy, and in the case of azole resistance in Aspergillus, has been linked to the widespread agricultural use of antifungals. This review, based on a workshop hosted by the Medical Research Council and the University of Exeter, illuminates the problem of antifungal resistance and suggests how this growing threat might be mitigated.
Keyphrases
- drug resistant
- healthcare
- sars cov
- antimicrobial resistance
- multidrug resistant
- candida albicans
- acinetobacter baumannii
- hiv aids
- antiretroviral therapy
- coronavirus disease
- escherichia coli
- human immunodeficiency virus
- mycobacterium tuberculosis
- hiv infected
- hepatitis c virus
- cell wall
- risk assessment
- respiratory syndrome coronavirus
- hiv testing
- mental health
- adverse drug
- emergency department
- bone marrow
- cystic fibrosis
- pulmonary tuberculosis
- plasmodium falciparum
- men who have sex with men
- young adults
- health insurance
- replacement therapy